Hemanext Inc.

Hemanext Inc. is a medical technology company based in Lexington, Massachusetts, specializing in advanced blood preservation and transfusion medicine solutions. The company's flagship product, Hemanext ONE®, is an FDA-authorized oxygen-controlled processing and storage system designed to preserve red blood cell (RBC) quality during refrigerated storage for up to 42 days. By removing and maintaining low oxygen levels throughout storage, Hemanext ONE® reduces oxidative storage lesions—progressive metabolic and structural damage that degrades RBC function and oxygen delivery capacity. The system preserves critical RBC parameters including membrane integrity, deformability, and metabolic stability, resulting in higher-quality blood products that maintain closer-to-physiological function. This innovation is particularly valuable for chronic transfusion patients (such as those with sickle cell disease) requiring lifelong transfusions, as well as trauma and resuscitation settings where blood quality directly impacts clinical outcomes. Hemanext operates on a consumable model facilitating seamless integration into existing hospital and blood center workflows, with CMS reimbursement recognition reflecting the clinical and economic value of oxygen-controlled RBC units.